4 Analysts Assess AnaptysBio: What You Need To Know
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have shared their insights on AnaptysBio (NASDAQ:ANAB), with ratings ranging from bullish to bearish. The average 12-month price target has increased by 26.79% to $53.25. Analysts from HC Wainwright & Co., JP Morgan, and Wedbush have maintained or raised their ratings and price targets. AnaptysBio is a clinical-stage biotechnology company focused on developing antibody product candidates for autoimmune and inflammatory diseases.
August 06, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on AnaptysBio (NASDAQ:ANAB) with a 26.79% increase in the average 12-month price target to $53.25. Key analysts from HC Wainwright & Co., JP Morgan, and Wedbush have maintained or raised their ratings and price targets.
The increase in the average 12-month price target by 26.79% and the maintenance or raising of ratings by key analysts suggest a positive short-term outlook for AnaptysBio. This is likely to boost investor confidence and potentially drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100